PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer
S. Suresh, S. Huard, A. Brisson, F. Nemati, C. Poulard, M. Ye, E. Martel, C. Reyes, D. C. Silvestre, D. Meseure, A. Nicolas, D. Gentien, M. Le Romancer, D. Decaudin, S. Roman-Roman, T. Dubois
This study identifies PRMT1 as a key regulator of EGFR and Wnt signaling in breast cancer and shows that targeting it with inhibitors can enhance chemotherapy and EGFR inhibitor efficacy in TNBC.
bioRxiv · Oct 22, 2021Cancer Biology